These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1712869)

  • 1. [Immunotherapy and urological malignancy].
    Marumo K
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):361-71. PubMed ID: 1712869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic response modifiers and urologic malignancies.
    Fleischmann J
    Surg Clin North Am; 1988 Oct; 68(5):1125-45. PubMed ID: 2459788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cellular therapy of urological neoplastic disease.
    Gold JE; Osband ME; Krane RJ
    Cancer Treat Rev; 1994 Apr; 20(2):173-90. PubMed ID: 8156540
    [No Abstract]   [Full Text] [Related]  

  • 4. Adoptive immunotherapy of urologic tumors.
    Belldegrun A; Rosenberg SA
    Cancer Treat Res; 1989; 46():213-33. PubMed ID: 2577191
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biological response modifiers and urological cancer].
    Ohmori H; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1992 Jun; 83(6):850-6. PubMed ID: 1501395
    [No Abstract]   [Full Text] [Related]  

  • 6. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N; Yamasaki S; Harada T; Satoh K; Ichinose Y; Moriguchi Y; Kodama H; Ohgaki K
    Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adoptive immunotherapy in malignant tumors].
    Kiselevskiĭ MV
    Vestn Ross Akad Med Nauk; 2003; (1):40-4. PubMed ID: 12608084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
    Wirth M
    Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer.
    Wirth M
    Urol Int; 1991; 47(4):219-30. PubMed ID: 1723554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunotherapy for urological tumours.
    Hrouda D; Muir GH; Dalgleish AG
    Br J Urol; 1997 Mar; 79(3):307-16. PubMed ID: 9117206
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferons and interleukins in metastatic renal cell carcinoma.
    Choudhury M; Efros M; Mittelman A
    Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of superficial bladder cancer.
    Shapiro A; Kadmon D; Catalona WJ; Ratliff TL
    J Urol; 1982 Nov; 128(5):891-4. PubMed ID: 6184490
    [No Abstract]   [Full Text] [Related]  

  • 16. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.